دورية أكاديمية
أعرض في EDS

Real-World Analysis of Outcomes and Economic Burden in Patients with Chronic Kidney Disease with and without Secondary Hyperparathyroidism among a Sample of the Italian Population.

التفاصيل البيبلوغرافية
العنوان: Real-World Analysis of Outcomes and Economic Burden in Patients with Chronic Kidney Disease with and without Secondary Hyperparathyroidism among a Sample of the Italian Population.
المؤلفون: Barbuto S; Nephrology, Dialysis and Kidney Transplant Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy., Perrone V; CliCon S.r.l., Società Benefit, Health, Economics & Outcomes Research, 40137 Bologna, Italy., Veronesi C; CliCon S.r.l., Società Benefit, Health, Economics & Outcomes Research, 40137 Bologna, Italy., Dovizio M; CliCon S.r.l., Società Benefit, Health, Economics & Outcomes Research, 40137 Bologna, Italy., Zappulo F; Nephrology, Dialysis and Kidney Transplant Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy., Vetrano D; Nephrology, Dialysis and Kidney Transplant Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy., Giannini S; Clinica Medica 1, Department of Medicine, University of Padova, 35128 Padova, Italy., Fusaro M; National Research Council (CNR), Institute of Clinical Physiology (IFC), 56124 Pisa, Italy.; Department of Medicine, University of Padova, 35128 Padova, Italy., Ancona DD; Pharmaceutical Department, ASL BAT (Barletta Andria Trani), 76123 Andria, Italy., Barbieri A; Direttore SC Farmaceutica Territoriale, ASL VC, 13100 Vercelli, Italy., Ferrante F; UOC Farmacia, Ufficio di Farmacovigilanza, ASL Frosinone, 03100 Frosinone, Italy., Lena F; U.O.C. Politiche del Farmaco, USL Toscana Sud Est, 58100 Grosseto, Italy., Palcic S; SC Farmacia Ospedaliera e Territoriale-Area Giuliana, Azienda Sanitaria Universitaria Integrata Giuliano-Isontina (ASUGI), 34128 Trieste, Italy., Re D; Servizio Farmaceutico Territoriale, ASL Teramo, 64100 Teramo, Italy., Rizzi FV; Pharmaceutical Department, ASL BAT (Barletta Andria Trani), 76123 Andria, Italy., Cogliati P; CSL Vifor, 00142 Rome, Italy., Soro M; CSL Vifor, 00142 Rome, Italy., Esposti LD; CliCon S.r.l., Società Benefit, Health, Economics & Outcomes Research, 40137 Bologna, Italy., Cianciolo G; Nephrology, Dialysis and Kidney Transplant Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.
المصدر: Nutrients [Nutrients] 2023 Jan 10; Vol. 15 (2). Date of Electronic Publication: 2023 Jan 10.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Publishing Country of Publication: Switzerland NLM ID: 101521595 Publication Model: Electronic Cited Medium: Internet ISSN: 2072-6643 (Electronic) Linking ISSN: 20726643 NLM ISO Abbreviation: Nutrients Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI Publishing
مواضيع طبية MeSH: Renal Insufficiency, Chronic*/complications , Renal Insufficiency, Chronic*/therapy , Hyperparathyroidism, Secondary*/epidemiology , Hyperparathyroidism, Secondary*/therapy , Hyperparathyroidism, Secondary*/complications, Adult ; Humans ; Retrospective Studies ; Financial Stress ; Renal Dialysis/adverse effects
مستخلص: This real-world analysis evaluated the clinical and economic burden of non-dialysis-dependent CKD patients with and without secondary hyperparathyroidism (sHPT) in Italy. An observational retrospective study was conducted using administrative databases containing a pool of healthcare entities covering 2.45 million health-assisted individuals. Adult patients with hospitalization discharge diagnoses for CKD stages 3, 4, and 5 were included from 1 January 2012 to 31 March 2015 and stratified using the presence/absence of sHPT. Of the 5710 patients, 3119 were CKD-only (62%) and 1915 were CKD + sHPT (38%). The groups were balanced using Propensity Score Matching (PSM). Kaplan-Meier curves revealed that progression to dialysis and cumulative mortality had a higher incidence in the CKD + sHPT versus CKD-only group in CKD stage 3 patients and the overall population. The total direct healthcare costs/patient at one-year follow-up were significantly higher in CKD + sHPT versus CKD-only patients (EUR 8593 vs. EUR 5671, p < 0.001), mostly burdened by expenses for drugs (EUR 2250 vs. EUR 1537, p < 0.001), hospitalizations (EUR 4628 vs. EUR 3479, p < 0.001), and outpatient services (EUR 1715 vs. EUR 654, p < 0.001). These findings suggest that sHPT, even at an early CKD stage, results in faster progression to dialysis, increased mortality, and higher healthcare expenditures, thus indicating that timely intervention can ameliorate the management of CKD patients affected by sHPT.
References: J Am Soc Nephrol. 2016 Jul;27(7):2135-47. (PMID: 26701975)
Clin Kidney J. 2021 Feb 05;14(10):2177-2186. (PMID: 34603696)
NDT Plus. 2008 Aug;1(Suppl 3):iii2-iii8. (PMID: 25983967)
Osteoporos Int. 2019 Oct;30(10):2019-2025. (PMID: 31190122)
BMC Nephrol. 2012 Oct 08;13:133. (PMID: 23043743)
Int J Oral Sci. 2015 Mar 23;7(1):8-13. (PMID: 25655009)
Am J Kidney Dis. 2013 Jun;61(6):899-909. (PMID: 23540260)
PLoS Genet. 2011 Sep;7(9):e1002292. (PMID: 21980298)
F1000Res. 2020 Sep 1;9:. (PMID: 32913635)
Clin J Am Soc Nephrol. 2013 Nov;8(11):1870-6. (PMID: 24135218)
Kidney Int. 2008 Jun;73(11):1296-302. (PMID: 18337714)
Health Serv Res. 2013 Jun;48(3):913-30. (PMID: 23046097)
Contrib Nephrol. 2017;190:83-95. (PMID: 28535521)
J Lab Physicians. 2021 Jul 14;14(2):144-150. (PMID: 35982879)
Kidney Int Suppl (2011). 2022 Apr;12(1):7-11. (PMID: 35529086)
PLoS One. 2013 Oct 16;8(10):e78475. (PMID: 24147135)
Clin Kidney J. 2021 Jan 20;14(10):2213-2220. (PMID: 34603697)
J Am Soc Nephrol. 2009 Feb;20(2):381-7. (PMID: 19073826)
N Engl J Med. 2004 Sep 23;351(13):1296-305. (PMID: 15385656)
Nephrol Dial Transplant. 2022 Mar 25;37(4):663-672. (PMID: 34021359)
Am J Kidney Dis. 2003 Oct;42(4 Suppl 3):S1-201. (PMID: 14520607)
Atherosclerosis. 2018 Apr;271:53-60. (PMID: 29459266)
Nephrol Dial Transplant. 2014 Jan;29(1):97-109. (PMID: 23975842)
J Bone Metab. 2020 Feb;27(1):1-13. (PMID: 32190604)
Int J Mol Sci. 2020 Jun 18;21(12):. (PMID: 32570711)
Br Med J. 1979 Apr 21;1(6170):1049-50. (PMID: 571747)
NDT Plus. 2008 Jan;1(Suppl 1):i2-i6. (PMID: 25983952)
Clin J Am Soc Nephrol. 2010 Nov;5(11):1946-53. (PMID: 20813860)
Nat Genet. 2009 Jun;41(6):712-7. (PMID: 19430482)
Clin Endocrinol (Oxf). 2001 May;54(5):575-82. (PMID: 11380487)
J Bone Miner Res. 2004 Sep;19(9):1531-8. (PMID: 15312255)
Kidney Int Suppl (2011). 2017 Jul;7(1):1-59. (PMID: 30675420)
Am J Clin Nutr. 2012 Sep;96(3):672-9. (PMID: 22854402)
Nephrol Dial Transplant. 2018 Mar 1;33(3):466-471. (PMID: 29156056)
Int J Nephrol. 2015;2015:184321. (PMID: 25918645)
Clin Chem. 2014 Mar;60(3):471-80. (PMID: 24281781)
Cureus. 2021 Jul 14;13(7):e16388. (PMID: 34408941)
Physiol Rev. 2012 Jan;92(1):131-55. (PMID: 22298654)
Lancet. 2013 Mar 30;381(9872):1125-34. (PMID: 23541053)
Circulation. 2021 Mar 16;143(11):1157-1172. (PMID: 33720773)
Arch Gerontol Geriatr. 2019 Jan - Feb;80:46-52. (PMID: 30343147)
Lancet. 2020 Feb 29;395(10225):709-733. (PMID: 32061315)
Ann Intern Med. 2009 May 5;150(9):604-12. (PMID: 19414839)
Nephrol Dial Transplant. 2021 Jan 1;36(1):160-169. (PMID: 33068419)
Clin J Am Soc Nephrol. 2010 Jun;5(6):1003-9. (PMID: 20299365)
J Nephrol. 2005 Jan-Feb;18(1):5-8. (PMID: 15772917)
PLoS One. 2013 Aug 05;8(8):e68870. (PMID: 23940515)
Curr Med Res Opin. 2008 Nov;24(11):3037-48. (PMID: 18826748)
Forum Health Econ Policy. 2020 Mar 5;23(1):. (PMID: 32134730)
G Ital Nefrol. 2012 Jul-Aug;29(4):445-51. (PMID: 22843156)
J Am Soc Nephrol. 2014 Oct;25(10):2169-75. (PMID: 24854271)
Am J Kidney Dis. 2013 Feb;61(2):211-8. (PMID: 22939518)
PLoS Med. 2016 Sep 20;13(9):e1002128. (PMID: 27648564)
Nephron Clin Pract. 2010;115(2):c94-9. (PMID: 20407272)
Kidney Int. 2013 Jan;83(1):121-8. (PMID: 22895520)
Adv Ther. 2021 Oct;38(10):5333-5344. (PMID: 34519948)
Am J Nephrol. 2016;44(4):316-325. (PMID: 27676085)
Aging (Albany NY). 2021 Jan 15;13(2):2982-3009. (PMID: 33460402)
Front Pharmacol. 2022 Oct 04;13:1020858. (PMID: 36267284)
فهرسة مساهمة: Keywords: CKD-MBD (Chronic Kidney Disease-Mineral Bone Disorder); active vitamin D; chronic kidney disease; native vitamin D; real-world evidence; secondary hyperparathyroidism
تواريخ الأحداث: Date Created: 20230121 Date Completed: 20230124 Latest Revision: 20230308
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC9867108
DOI: 10.3390/nu15020336
PMID: 36678208
قاعدة البيانات: MEDLINE
الوصف
تدمد:2072-6643
DOI:10.3390/nu15020336